We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
DUTASTERIDE/TAMSULOSIN SANDOZ (Sandoz Pty Ltd)
Product name
DUTASTERIDE/TAMSULOSIN SANDOZ
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
142 (255 working days)
Active ingredients
dutasteride, tamsulosin hydrochloride
Registration type
New generic medicine
Indication
Dutasteride/Tamsulosin Sandoz is indicated for the management of moderate to severe symptomatic benign prostatic hyperplasia (BPH).